Jordi Remon: Comparison of treatments in EGFRm NSCLC at ASCO24

Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:

“For patients with EGFRm Osi-Progression NSCLC, there is no homogeneous benefit in PFS with antiangiogenic + io+CT vs CT and no mature OS benefit.

Phase 3 HARMONI-3 trial (ivonescimab (bispecific VEGF/PD1 Ab) + CT vs CT is pending. Data in Chinese patients looks similar to previous (HARMONI-A).”

Source: Jordi Remon/X